The CDC recently published updates to vaccine-specific and general recommendations:

Influenza vaccine, 2022-2023

The main changes are described in the summary:

First, the composition of 2022–23 U.S. influenza vaccines includes updates to the influenza A(H3N2) and influenza B/Victoria lineage components … Second, the approved age indication for the cell culture–based inactivated influenza vaccine, Flucelvax Quadrivalent (ccIIV4), was changed in October 2021 from ≥2 years to ≥6 months. Third, ... ACIP recommends that adults aged ≥65 years preferentially receive any one of the following higher dose or adjuvanted influenza vaccines: quadrivalent high-dose inactivated influenza vaccine (HD-IIV4), quadrivalent recombinant influenza vaccine (RIV4), or quadrivalent adjuvanted inactivated influenza vaccine (aIIV4). If none of these three vaccines is available at an opportunity for vaccine administration, then any other age-appropriate influenza vaccine should be used.

Review the complete recommendation.

15-valent pneumococcal conjugate vaccine

Providers can now offer PCV15 as an alternative to PCV13 in children younger than 19 years of age.

Review the complete recommendation.

Cholera vaccine

Per the summary:

This report describes previously published ACIP recommendations about use of CVD 103-HgR for adults aged 18–64 years and introduces a new recommendation for use in children and adolescents aged 2–17 years. ACIP recommends CVD 103-HgR, the only cholera vaccine licensed for use in the United States, for prevention of cholera among travelers aged 2–64 years to an area with active cholera transmission. Health care providers can use these guidelines to develop the pretravel consultation for persons traveling to areas with active cholera transmission.

Review the complete recommendation.

General recommendations

Three updates were made to the general recommendations in September 2022:

  • Related to “Timing and Spacing of Immunobiologics – Unknown or Uncertain Vaccination Status,” the text was updated to emphasize that serology is not recommended as an alternative to vaccination, except for dengue virus. See the update (p. 27).
  • Related to “Vaccine Administration,” the shape in figure 3, indicating the location for vaccination on the deltoid, was altered to align with other CDC materials. See the updated figure (p. 106).
  • Related to “Altered immunocompetence,” the recommendations related to timing of recombinant zoster vaccine following hematopoietic stem cell transplant were updated, depending on whether the transplant introduced cells from the individual (autologous) or a donor (allogeneic). See the update (p. 132).

For more detailed descriptions of these updates or to see updates implemented earlier this year or in previous years, visit the “List of Errata/Updates” webpage.

Materials in this section are updated as new information and vaccines become available. The Vaccine Education Center staff regularly reviews materials for accuracy.

You should not consider the information in this site to be specific, professional medical advice for your personal health or for your family's personal health. You should not use it to replace any relationship with a physician or other qualified healthcare professional. For medical concerns, including decisions about vaccinations, medications and other treatments, you should always consult your physician or, in serious cases, seek immediate assistance from emergency personnel.